MEC Plus

Biosimilars Implementation in the United States: Where Opportunities Remain
Biosimilars Implementation in the United States: Where Opportunities Remain
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
How Far Have We Gone with Biosimilars?
How Far Have We Gone with Biosimilars?
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
The Challenges of Biosimilars in the Daily Oncology Practice?
The Challenges of Biosimilars in the Daily Oncology Practice?
Dina B. Dumercy McHenry, PharmD, MBA, BCOP
Clinical Update: Biosimilars to Adalimumab
Clinical Update: Biosimilars to Adalimumab
Johnny Chang, PharmD, BCPS, CSP
Bladder Cancer Updates
Bladder Cancer Updates
Petros Grivas, MD, PhD
Moving the Needle on Bladder Cancer Survival: A Urologist's Perspective
Moving the Needle on Bladder Cancer Survival: A Urologist's Perspective
Marc Dall'Era - MD
Bladder Cancer Updates
Bladder Cancer Updates
Petros Grivas, MD, PhD
Bladder Cancer Update
Bladder Cancer Update
Benjamin Garmezy, MD
Bladder Cancer Update
Bladder Cancer Update
Benjamin Garmezy, MD
Bladder and Kidney
Bladder and Kidney
Manojkumar Bupathi, MD, MS
Bladder and Kidney
Bladder and Kidney
Manojkumar Bupathi, MD, MS
Bladder / Urothelial Cancer Updates
Bladder / Urothelial Cancer Updates
Petros Grivas, MD, PhD
Bladder Cancer Updates
Bladder Cancer Updates
Petros Grivas, MD, PhD
How I Treat Metastatic Bladder Cancer in 2023
How I Treat Metastatic Bladder Cancer in 2023
Benjamin Garmezy, MD
Bladder Cancer Updates
Bladder Cancer Updates
Yousef Zakharia, MD
Bladder Cancer Updates
Bladder Cancer Updates
Yousef Zakharia, MD
Bladder Cancer: Novel Insights and Recent Approvals
Bladder Cancer: Novel Insights and Recent Approvals
Mark Matrana, MD, MS, FACP